Core Insights - Vor Bio reported financial results for Q4 and full year 2024, highlighting advancements in their cell and genome engineering platform and clinical trials for trem-cel and VCAR33 [1][2] Corporate Updates - Trem-cel is being developed as a shielded transplant for patients with AML and MDS, genetically engineered to remove CD33, allowing for targeted therapies post-transplant [3] - VCAR33 is a transplant donor-derived anti-CD33 CAR-T cell therapy for AML patients who have relapsed after standard care or trem-cel transplant [5] - The combination of trem-cel and VCAR33 has the potential to improve patient outcomes in AML and set a new standard of care for high relapse risk patients [6][10] Clinical Trials and Data Updates - Upcoming clinical data updates for VCAR33 are expected in the first half of 2025, while updates for trem-cel + Mylotarg are anticipated in the second half of 2025 [7][16] - The latest data from the VBP101 trial showed durable engraftment and improved relapse-free survival in patients treated with trem-cel and Mylotarg [8] - Enrollment in the VBP301 study is ongoing, with encouraging CAR-T expansion data reported [9] Financial Position - Vor Bio completed a $55.6 million private placement in December 2024, enhancing its financial position [11] - As of December 31, 2024, the company had cash, cash equivalents, and marketable securities totaling $91.9 million, projected to fund operations into Q1 2026 [16] - R&D expenses for Q4 2024 were $25.3 million, up from $20.9 million in Q4 2023, while total operating expenses for the year were $121.2 million, down from $126.0 million in 2023 [16][21] Board and Leadership Changes - Erez Kalir was appointed to Vor Bio's Board of Directors as part of the recent financing transaction, bringing extensive experience in life sciences and technology [12]